LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
LifeMD, Inc. (LFMD)
Company Research
Source: GlobeNewswire
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy® program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations and $600 for oral therapy. "Our inclusion in the Wegovy® subscription program is a natural extension of our established relationship with Novo Nordisk," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "This program deepens the value of our collaboration and adds m
Show less
Read more
Impact Snapshot
Event Time:
LFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LFMD alerts
High impacting LifeMD, Inc. news events
Weekly update
A roundup of the hottest topics
LFMD
News
- Novo to sell Wegovy subscriptions on Hims, LifeMD, and others [Seeking Alpha]Seeking Alpha
- LifeMD: Comparing The High Yield Preferred Stock To An Options Income Strategy [Seeking Alpha]Seeking Alpha
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockGlobeNewswire
- LifeMD appoints Atul Kavthekar as CFO [Seeking Alpha]Seeking Alpha
- LifeMD (LFMD) was upgraded by Mizuho from "neutral" to "outperform". They now have a $8.00 price target on the stock, up from $6.00.MarketBeat
LFMD
Earnings
- 3/9/26 - Beat
LFMD
Sec Filings
- 4/1/26 - Form 4
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- LFMD's page on the SEC website